Brian Schwartz - Chinook Therapeut | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 9 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Felzartamab (Anti-Cd38) in Patients with IgA Nephropathy-interim Results from the IGNAZ Study

Juergen Floege, Richard Lafayette,Jonathan Barratt,Brian Schwartz, Paul T. Manser, Uptal D. Patel, Lilia Pineda, Nicola Faulhaber,Rainer Boxhammer, Stefan Haertle,Anjali Thakur, Sean Barbour

NEPHROLOGY DIALYSIS TRANSPLANTATION (2024): I252-I253

Cited0Views0Bibtex

#425 Felzartamab (Anti-Cd38) in Patients with IgA Nephropathy—interim Results from the IGNAZ Study

Jürgen Floege,Richard Lafayette,Jonathan Barratt,Brian Schwartz, Paul T Manser,Uptal D Patel, Lilia Pineda,Nicola Faulhaber,Rainer Boxhammer,Stefan Haertle,Anjali Thakur,Sean Barbour

Nephrology Dialysis Transplantationno. Supplement_1 (2024)

Cited0Views0Bibtex

Chk-336, a first-in-class orally administered ldh inhibitor: safety, pk and target engagement in a first-in-human phase 1 healthy volunteer study

Vincent Tong,Brian Schwartz,Chun Lam,John Knight,Sonia Fargue, David A. Wagner,Harvey Wong, Lei Wang,Hetal Kocinsky, Valerie Fauvelle,Andrew King

NEPHROLOGY DIALYSIS TRANSPLANTATIONno. Supplement_1 (2023): I11-I11

Cited0Views0Bibtex

WCN23-1175 UPDATED INTERIM RESULTS OF A PHASE 1/2 STUDY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY

J. Barratt,S.G. Kim, I. Agha, L. Kooienga, A. Madan, P. Ruiz-Ramon, H. Thomas, B. Workeneh, R. Narayanan, B. Sorensen,B.M. Schwartz,A.J. King,C. Jones-Burton, E.Y. Lee

Kidney International Reportsno. 3 (2023): S280-S281

Cited0Views0Bibtex

WCN23-1107 A PHASE 1/2 MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIS OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IgA NEPHROPATHY

S.G. Kim, E.Y. Lee, R. Narayanan, B. Sorensen,B.M. Schwartz,A.J. King,C. Jones-Burton,J. Barratt

Kidney International Reportsno. 3 (2023): S280-S280

Cited0Views0Bibtex

MO207: A Phase 1/2, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IGA Nephropathy

Jonathan Barratt,Brian Schwartz,Bess Sorensen, Margaret Macdonald, Jerlyn Tolentino,Jeannette Lo,Andrew King,Sai Prasad N. Iyer,Alan Glicklich

Nephrology, dialysis, transplantation/Nephrology dialysis transplantationno. Supplement_3 (2022)

Cited1Views0Bibtex

Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy

Jonathan Barratt,Laura Kooienga,Irfan Agha, Hanna Thomas,Biruh Workeneh,Sai Prasad N. Iyer, Rangaraj Narayanan, Taher Sathaliya,Bess Sorensen,Brian S. Schwartz,Andrew J. King

Journal of the American Society of Nephrologyno. 11S (2022): 503-503

Cited0Views0Bibtex

MO212: Updated Interim Results of A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IGA Nephropathy

Jonathan Barratt,Laura Kooienga,Billy Hour,Irfan Agha,Brian Schwartz,Bess Sorensen,Jeannette Lo,Andrew King, Taher Sathaliya,Sai Prasad N. Iyer,Aaron Endsley,Alan Glicklich

Nephrology, dialysis, transplantation/Nephrology dialysis transplantationno. Supplement_3 (2022)

Cited1Views0Bibtex

Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1/2 Trial

Jonathan Barratt,Billy T. Hour,Brian S. Schwartz,Bess Sorensen,Suzanne E. Roy, Colleen L. Stromatt, Margaret MacDonald,Aaron N. Endsley,Jeannette Lo,Alan Glicklich,Andrew J. King

Journal of the American Society of Nephrologyno. 10S (2021): 509-509

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn